Meeting
2024 ASCO Annual Meeting
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
Authors
Elena Garralda
Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Elena Garralda , Judy S. Wang , Andrew G. Gianoukakis , Matthew H. Taylor , David R. Spigel , Sarina A. Piha-Paul , Daniel Morgensztern , Susanne M. Arnold , Guzman Alonso , Miguel García-Pardo , Javier García-Corbacho , Martin Forster , Matthew G Krebs , Antoine Italiano , Vivek Subbiah , Sonia Serrano , Geoff Fisher , Sue Brook , Hendrik-Tobias Arkenau , Pilar Garrido
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05443126
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8556)
DOI
10.1200/JCO.2024.42.16_suppl.8556
Abstract #
8556
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
First Author: Caicun Zhou
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
First Author: Nathan A. Pennell
Poster
2019 ASCO Annual Meeting
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
First Author: Patrick Schoffski
Poster
2020 ASCO Virtual Scientific Program
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
First Author: Justin F. Gainor